Overall cohort | Rituximab treatment | No Rituximab treatment | P value | |
---|---|---|---|---|
Patient number, N (%) | 80 (100) | 45 (56) | 35 (44) | / |
Age at diagnosis, years | 37 (18–64) | 38 (19–64) | 35 (18–58) | 0.485 |
Gender, N (%) | 0.360 | |||
Male | 33 (41) | 21 (47) | 12 (34) | |
Female | 47 (59) | 24 (53) | 23 (66) | |
B symptoms, N (%) | 40 (50) | 26 (58) | 14 (40) | 0.176 |
LDH elevated, N (%)a | 58 (79) | 33 (75) | 25 (86) | 0.841 |
LDH level at diagnosis, median U/l (range) | 329 (145–1450) | 327 (112–1277) | 376 (145–1450) | 0.439 |
Ann Arbor stage, N (%) | 0.396 | |||
I | 11 (14) | 8 (18) | 3 (8) | |
II | 49 (61) | 26 (58) | 23 (66) | |
III | 15 (19) | 7 (15) | 8 (23) | |
IV | 5 (6) | 4 (9) | 1 (3) | |
Extranodal sites involved, N (%) | 0.536 | |||
no | 68 (85) | 37 (82) | 31 (89) | |
yes | 12 (15) | 8 (18) | 4 (11) | |
ECOG, N (%) | 0.344 | |||
0 | 58 (73) | 33 (73) | 25 (71) | |
1 | 20 (25) | 12 (27) | 8 (23) | |
2 | 2 (2) | 0 (0) | 2 (6) | |
IPIb, N (%) | 0.397 | |||
Low risk | 50 (66) | 32 (71) | 18 (58) | |
Low-intermediate risk | 13 (17) | 7 (16) | 6 (19) | |
High-intermediate risk | 12 (16) | 5 (11) | 7 (23) | |
High risk | 1 (1) | 1 (2) | 0 (0) |